It’s been just five months since Eli Lilly breast cancer drug Verzenio hit the market, but the product has racked up its third approval, broadening its group of eligible patients and putting it on more even footing with rivals from Pfizer and Novartis.Original Article
Eli Lilly nabs another breast cancer approval for third-to-the-party Verzenio
